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ABSTRACT 
Improving neurodevelopmental outcome for preterm infants is an important challenge 
for neonatal medicine. The disruption of normal brain growth and neurological 
development is a significant consequence of preterm birth and can result in physical 
and cognitive impairments. Whilst advances in neonatal medicine have led to 
progressively better survival rates for preterm infants, there has only been a modest 
improvement in the proportion of surviving infants without neurological impairment, 
and no change in the proportion with severe disability. The overall number of 
children with neurodisability due to prematurity is increasing. Trials investigating 
novel therapies are underway and many have promising early results, however, in the 
interim, current treatments and management strategies that have proven benefit for 
neurodevelopment or reduction in neonatal brain injury, are often underutilised. We 
collate the evidence for the efficacy of such interventions, recommended by guidelines 
or supported by large meta-analysis or randomised control trials. We address 
controversies that have hindered uptake and problems with translating research into 
practice. We then look to the future of preterm neuroprotective care. 
 
INTRODUCTION 
Survival rates for preterm babies are increasing,1 however severe neurological 
impairment remains a significant consequence of preterm birth.2 3 Research continues 
into potential treatments for reducing both the risk of initial brain injury and 
subsequent neurodevelopmental problems;4 however, in the interim, these can be 
reduced by optimising currently approved and recommended practices. 
 
Methods 
Medline, Web of Science, the Cochrane database, national and international 
guidelines were searched for meta-analyses and randomised control trials (RCTs) of 
interventions affecting neurodevelopment and/or intraventricular haemorrhage (IVH) 
in preterm infants. We reviewed compliance using the National Neonatal Audit 
Programme (NNAP)5 – an audit of nearly all UK neonatal units and the UK Vermont 
Oxford Network database (VON)6, which covers 25% of UK very low birth weight 
deliveries.   
 
ANTENATAL INTERVENTIONS 
Neural development and brain growth are fundamentally affected by the in utero 
environment.7 Reducing antenatal risk, including rates of preterm labour is important, 
but beyond the scope of this review. Following onset of preterm labour, 
neuroprotective interventions can be implemented. 
 
Antenatal Transfer for Anticipated Preterm Delivery 
Mortality for extremely preterm infants (22-26 weeks) is reduced in centres offering 
the highest level of intensive care (tertiary centres), compared to less specialist centres 
(Odds Ratio (OR) 0.73 (95% confidence interval (95%CI) 0.59-0.9)),8 supporting the 
recommendation that care is centralised.9 Transport of these infants during the first 
48hours is however associated with increased rates of severe IVH,10 and babies born 
in tertiary centres have significantly better morbidity-free survival than infants 
transferred there after birth (OR 1.92 (95%CI 1.02-3.6)).8 Despite guidance, only 56% 
of births in England at 22-26 weeks occurred in tertiary centres in 2006.8 Whilst the 
difference in morbidity is likely multifactorial10, the findings emphasise the 
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importance of coordinated neonatal and obstetric network strategies for safe antenatal 
centralisation. 
 
Antenatal Steroids 
Antenatal steroid therapy is one of the most important advances in perinatal care and 
has played a significant role in improving survival rates.11 The delay in translating 
research on the benefits of antenatal steroids into clinical practice was a main driver 
for the establishment of the Cochrane Collaboration12, and consequently antenatal 
steroids are recommended for all women with threatened preterm delivery before 
34weeks gestation.13 Despite this, only 54% of mothers in low and middle income 
countries are offered them14 while 85% of eligible deliveries received one or more 
doses of antenatal steroid in the UK.15 Notably only 67% of liveborn infants at 23 
weeks were treated, and 25% of units had rates of 25% or lower.16 
Incidence of IVH and white matter damage are reduced following antenatal steroids11 
17(Table 1). This is secondary to vasoconstriction of cerebral vessels and anti-
inflammatory effects, as well as increased cardiovascular stability related to reduced 
respiratory compromise.18 
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Table 1: Impact on rates of adverse neurodevelopmental outcome for 
specified interventions  
(IVH = Intraventricular Haemorrhage; CP = Cerebral Palsy; PVL = Periventricular 
Leukomalacia; RR = Relative Risk; AOR = Adjusted Odds Ratio) 
 
 
Intervention Outcome Affected Risk Adjustment 
Antenatal Steroids IVH (all grades) RR 0.54 [0.43-0.69]11 
 Developmental Delay (3 years) RR 0.49 [0.24-1.00]11 
 CP (all severities 2-6 years) RR 0.60 [0.34-1.03]11 
 
Magnesium Sulphate in Labour CP (all severities 12-24 months) RR 0.68 [0.54- 0.87]19 
 CP (severe and moderate 12-24 months) RR 0.64 [0.44-0.92]19 
 Gross Motor Dysfunction (18-24 months) RR 0.61 [0.44-0.85]19 
Delayed Cord Clamping IVH (all grades) 
 
Gross Motor Dysfunction (18-22 months) 
 
RR 0.59 [0.41-0.85]20 
 
OR 0.32 [0.10-0.90]21 
Caffeine CP (all severities 12-22 months) AOR 0.58 [0.39-0.87]22  
 Cognitive Delay (18-22 months) AOR 0.81 [0.66-0.99]22  
Prophylactic Indomethacin IVH (Grades 3 and 4) RR 0.66 [0.53 -0.82]23 
 Ventriculomegaly, PVL or other white 
matter echo-abnormalities 
RR 0.80 [0.65-0.97]23 
Volume Ventilation PVL and IVH (Grade 3 and 4) RR 0.48 [0.28-0.84]24 
 
 
Meta-analysis shows lower rates of developmental delay and CP, and higher cognitive 
ability in children who received antenatal steroids compared to those who did not.11 
Outcome was improved after a single course, even if preterm delivery was arrested.25 
Evidence demonstrates benefits to the neonate with minimal risks to the mother, 
following delivery within seven days of a single complete course of corticosteroids.11 
This includes cases where tocolysis has been used to delay delivery for treatment, 
even in the presence of chorioamnionitis.26 
 
A RCT is currently comparing outcomes following betamethasone verses 
dexmethasone27 since both are used with differing evidence as to which is safest and 
best.28 29 30 Likewise, the evidence for repeating treatment if delivery has not occurred 
within seven days is mixed. Meta-analysis revealed that infants exposed to multiple 
steroid courses have lower risk of early respiratory morbidity, but tend to have 
reduced birth weight and head circumference.31 Current guidance advises against 
multiple courses, although a single additional rescue course may be appropriate when 
the first was before 26 weeks gestation.28 
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Magnesium Sulphate (MgSO4) 
MgSO4, a drug widely used in obstetrics,
32 was recognised as a potential 
neuroprotectant when data revealed a reduced  incidence of IVH in babies whose 
mothers had received it.33 Subsequently a decrease in the incidence of CP was 
presented34 and animal models and clinical trials have since corroborated these 
findings.19 MgSO4 acts as a non-competitive inhibitor at NMDA channels, blocking 
excess glutamate release, reducing excitotoxicity, and consequently oligodendroglial 
progenitor cell death,35 as well as modulating the effects of pro-inflammatory 
cytokines which are known to correlate with neurological outcome.36 In addition, due 
to MgSO4’s vasoactive properties, further benefit may result from stabilisation of 
blood pressure37 and cerebral arterial perfusion.38 
The overall risk of CP, the risk of severe and moderate CP and the incidence of gross 
motor dysfunction19 (Table 1) is reduced following antenatal MgSO4. To date, no 
neurodevelopmental advantage has been seen in later childhood39 40, however 
individual studies are underpowered to show this. As with many interventions, the 
lack of proven benefit to composite outcome in older children should not negate the 
positive early effects.41 
MgSO4 for neuroprotection prior delivery at <30 weeks is recommended 
internationally42-44 with consideration in deliveries <34 weeks also advocated in some 
regions.13 Uptake has however been sub-optimal. Only 38% of eligible UK infants 
<30 weeks registered on VON received antenatal MgSO4 in the UK in 2014 and in 
25% of units the rate was less than 16.8%.16 From a very recent NNAP report45 
estimated uptake is similar (36%), although data reporting was incomplete. Concerns 
about hypotonia and respiratory depression at birth, consequent to MgSO4’s blockade 
of calcium into cells, are commonplace, but have not been demonstrated in large 
cohort studies or in the meta-analysis.46 47 Furthermore, since MgSO4 has anti-
inflammatory effects, there have been concerns that it may increase sepsis. Although 
significant neuroprotective effects were not identified in the setting of 
chorioamnionitis48, there is no evidence that infection risks are increased.15 The 
potential benefits of MgSO4 for preterm deliveries 30-34 weeks are being studied, to 
provide clearer evidence at these higher gestations.49  
The MagNET trial50 reported an increase in fetal death in mothers following MgSO4 
versus the control group. This concerning difference was only significant when 
MgSO4 was used at high doses, and was not seen in meta-analysis.
19 Cumulative high 
doses of MgSO4 (>50g) are associated with IVH and increased mortality
51 52 making 
clear guidance on dosing crucial. Developing this is impeded by the variability in 
evidence.19 35 53 Differing dosing schedules, trial inclusion criteria and mixed intent 
(obstetric vs. fetal neuroprotective) complicate interpretation.53 A blinded RCT is 
underway with a view to obtaining more conclusive evidence54 since previous 
investigation found a lack of data comparing different regimens.53 Currently 4g 
loading dose over 20-30minutes followed by an infusion of 1g/hour until birth or for a 
maximum of 24hours is endorsed in the UK.13 55 
Management of Preterm Prelabour Rupture of Membranes (PPROM) to Reduce 
Chorioamnionitis and Early Onset Infection (EOS) 
Chorioamnionitis and infections within the first 72 hours of life (EOS) contribute to 
adverse neurodevelopmental outcome56 57 (Table 2). Cerebral hypoperfusion, capillary 
thrombosis and increased permeability of the blood brain barrier - allowing direct 
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passage of microbial products and proinflammatory cytokines into the cerebral tissue, 
have been suggested to cause fetal brain injury.58 Several key biomarkers have been 
identified as targets for future treatments to promote normal neurological 
development in the presence of antenatal infection,57 however prevention of 
chorioamnionitis following PPROM is currently the mainstay of recommendations. 
Prophylactic antibiotics and consideration of immediate delivery after 34 weeks are 
advocated in the UK59, however both are controversial. 
 
Table 2: Impact of acute morbidities on adverse neurodevelopmental outcome 
(CP = cerebral palsy; NEC = necrotising enterocolitis; EOS = early onset sepsis; 
LOS = late onset sepsis; OR = odds ratio; AOR = adjusted odds ratio). 
 
 
Acute Morbidity Neurodevelopmental Outcome Risk Adjustment 
  EOS- OR 1.7 (0.84-3.45)56 
Infection CP (all types- 5 years) LOS – OR 1.71 (1.14-2.56)56 
  EOS +LOS OR 2.33 (1.02 – 
5.33)56 
NEC Neurological impairment (18-22months) AOR 1.7 (1.2, 2.4)60 
 Diparetic CP (after surgical NEC + bacteraemia 
-24 months) 
OR 8.4 (1.9- 39)61 
 
 
Antibiotics following PPROM (without chorioamnionitis) leads to prolongation of 
pregnancy, reduction in neonatal infection (Relative Risk (RR) 0.67, 95%CI 0.52- 
0.85)62 and fewer abnormal cranial ultrasound scans (RR 0.81, 95%CI 0.68 to 0.98).62 
At school age however, there was no difference in functional, behavioural or 
attainment outcomes63 but increased levels of functional impairment were seen in 
children of mothers who had received erythromycin following spontaneous onset of 
preterm labour with intact membranes64 making correct diagnosis essential.  
 
Timing of delivery following PPROM, without evidence of infection or fetal 
compromise, is also complex. Delayed delivery increases the risk of 
chorioamnionitis65, however this needs to be balanced against the risks of preterm 
birth. Meta-analysis concluded that there was insufficient evidence to advocate either, 
in part since protocols were not comparable to current best practice.66 Recent RCTs67 
68 have reported no difference in the incidence of neonatal sepsis,67 68 morbidity or 
mortality67 but increases in preterm complications were seen making recommendation 
for immediate delivery contentious.67 
 
POSTNATAL INTERVENTIONS 
Following delivery, physiological instability and systemic inflammation predispose 
the preterm brain to IVH and white matter damage.69 Careful consideration and 
minimisation of these can protect the premature brain. 
 
Deferred Cord Clamping (DCC) 
DCC in preterm infants leads to reduction in mortality and multisystem morbidity 
including all grades of IVH.70 71 20 Recent studies21 have shown improved motor 
function at 18-22months (Table 1) whereas previously, no difference in 
developmental outcome had been recognised.20 Several mechanisms for the positive 
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effects are hypothesised72 including increased blood volume and oxygenation, 
prevention of iron deficiency anaemia, and the transfer of stem and progenitor cells 
with extensive proliferative capacity which may contribute to repairing tissues and 
promoting immunocompetence.21 Although DCC is recommended when the infant is 
born in good condition without the need for resuscitation,13 73 immediate clamping 
often predominates.42  
 
Hesitancy arises from the lack of consensus on optimal timing for DCC and theorised 
risks such as potential volume overload, polycythaemia, jaundice, and interruption of 
collection of blood for cord blood banking.20 42 74 Concerns about delayed 
resuscitation, thermal care and technical difficulties are being addressed through the 
development and trialing of new equipment to allow transition to be assisted closer to 
the mother with the cord intact. 75 76 Studies have shown DCC to be feasible, safe and 
to have significant benefit to preterm infants, with no detriment from the risks above. 
20 77  
 
Caffeine for Apnoea of Prematurity 
Recurrent apnoeas, are common in preterm infants, and are potentially harmful.78 In 
RCT, treatment with caffeine in the first 10days decreased the incidence of CP and 
cognitive impairment at 18–21months in low birth-weight at risk infants.22 This effect 
was only partially explained by the reduction in bronchopulmonary dysplasia, a co-
morbidity that is independently associated with adverse neurodevelopmental 
outcome.22 79 Caffeine has been shown to be safer than other methylxanthines and is 
recommended as a treatment for preterm infants.78 
 
Opinion varies as to when to start caffeine. It is hypothesised that starting caffeine 
early, prior to the period of greatest vulnerability to white matter injury, may be 
beneficial80, however, the only significant benefit seen from this has been the 
incidence of a persistent ductus arteriosus (PDA).81 Subsequent studies have shown a 
reduction in death, bronchopulmonary dysplasia and PDA for infants given caffeine 
in the first three days of life compared to those who received it later 82 83 and a RCT is 
currently recruiting to investigate prophylactic verses therapeutic caffeine further.84 
 
Notably, the neuroprotective effect of caffeine was not significant at five years due to 
reduced statistical power.85 Increased incidence of cerebellar haemorrhage on MRI 
has been reported following high dose caffeine,80 however, there is extensive 
evidence that caffeine is safe at standard doses, and has lasting multi-system benefits 
for preterm infants.78 
 
Indomethacin Prophylaxis for PDA 
Closure of the ductus arteriosus is delayed in up to 80% of infants born at <25 
weeks86 and as many as 70% <28 weeks.86 PDA can be associated with IVH and 
abnormalities of cerebral perfusion as well as cardiac and pulmonary complications.86 
Optimal management is a topic of great debate - whilst overall prevalence is high, one 
third resolve without intervention and not all of those that persist become clinically 
significant.87 88 Trials investigating early versus late treatment of infants with known 
PDA (targeted treatment) have not shown any difference in mortality or cranial 
ultrasound abnormalities, leading authors to hypothesise that detriment occurs before 
the PDA becomes clinically significant.89 Additionally, targeting treatment depends 
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on access to echocardiographic expertise, which is not universal. Both the timing of 
intervention, and the need to treat at all are contested.88 
 
Indomethacin prophylaxis significantly reduces the incidence of severe IVH and led 
to a borderline significant reduction in ventriculomegaly, periventricular 
leukomalacia (PVL) or other white matter echo-abnormalities23 (Table 1). There was 
no difference in mortality, necrotising enterocolitis (NEC) or other complications.23 
Fewer infants required surgical ligation following prophylaxis,23 hence were not 
exposed to the risks of cardiac surgery, which include detriment to 
neurodevelopment.90 In addition to closing, and therefore reducing the haemodynamic 
consequenses of, the PDA, it is postulated that indomethacin may have a direct effect 
on the brain. It reduces prostaglandin synthesis and the cerebral vascular hyperemic 
response as well as promoting the maturation of the basement membrane and basal 
lamina making the brain less vulnerable to hypoxic, hypercapnic and hypertensive 
insults.91 Prophylaxis based on risk criteria has shown the effect of prophylactic 
indomethacin is more significant in infants at higher risk of IVH.92 93 
 
 
Practice is varied, with limited uptake despite convincing neonatal results.97 
Indomethacin can be difficult to source, with supply limiting both clinical use and 
research and89 no difference in developmental outcome at 18-36months was seen in 
meta-analysis.23 There are concerns this may be due to detriment caused to infants 
without a PDA, or those in whom it would close spontaneously.94 89  
 
There is however no evidence of harm, and a significant reduction in cognitive 
disability at 4–5 years95 and better language development in boys at 8 years96 have 
since been reported following prophylactic indomethacin. The harms of potentially 
unnecessary intervention in some need to be balanced against the benefit for others, 
yet the current cumulative evidence is that prophylactic indomethacin is safe and 
pertains to short-term neonatal advantages which are linked with improved 
neurodevelopmental outcome.23 
 
Volume Targeted Ventilation to Prevent Hypocarbia 
Although antenatal steroids and surfactant have significantly reduced rates of 
mechanical ventilation, 69% of VON-registered UK infants <1500g were ventilated in 
2014.16 This can lead to hypocarbia, causing changes in cerebral blood flow and 
perfusion pressure, predisposing to PVL.24 Meta-analysis revealed a statistically 
significant reduction in hypocarbia in patients receiving volume-targeted ventilation 
compared to pressure-limited ventilation.24 This translated into a reduction in the 
combined outcome of PVL or grade 3–4 IVH24 (Table 1). Although current data is 
underpowered to determine impact on long-term neurodevelopment, these short term 
benefits in reducing detectable brain injury, the mechanistic validity and the lack of 
demonstrable harm, provide a strong basis for using volume-targeted ventilation 
modes, when mechanical ventilation is required.24  
Risk is theoretically reduced further through end tidal or transcutaneous capnography, 
through earlier detection and therefore earlier correction of hypocarbia, however there 
is currently insufficient evidence to recommend or refute this.98 99 
Preventing Causative Morbidities 
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Late onset sepsis (LOS), NEC and poor nutritional status are associated with adverse 
neurodevelopmental outcomes for preterm infants (Table 2).56 100 101 A detailed 
exploration of the relative importance of different strategies to reduce their incidence 
is complex and beyond the scope of this review since there are no consensus 
recommendations and trials are ongoing, however some key interventions are briefly 
highlighted. 
 
Late Onset Sepsis 
Approximately 21–36% of very low birth weight preterm infants have LOS.56 102 100 
Neurodevelopmental impairment is increased following clinical infection as well as 
culture positive sepsis and meningitis when compared to infants without suspected 
sepsis103 and the risk is increased further in infants who have experienced both EOS 
and LOS as a ‘double hit’.56 
 
Standardised care ‘bundles’ for central lines - setting and enforcing standards for 
insertion, maintenance and timely removal, decrease infections by up to 67%.104 
Implementation of such a bundle resulted in improved cognitive outcome at 2 years in 
one report.105 Antimicrobial stewardship, limited postnatal steroid use, early enteral 
feeding with breast milk and meticulous hand hygiene are important and cost-
effective strategies for reducing the burden of LOS.104 Preliminary data also suggests 
bovine lactoferrin supplementation alone and in combination with probiotics may 
reduce LOS with a large study now recruiting.106 Immune replacement therapy is 
being investigated,104 107 and prophylactic fluconazole in at risk populations has been 
shown to reduce invasive candidiasis.104 
 
Necrotising Enterocolitis 
NEC is associated with structural brain injury61 108 and poor neurodevelopmental 
outcome (Table 2).60 61 108 NEC requiring surgery is associated with worse outcomes 
than NEC treated with antibiotics and withholding feeds109, and the duration of NEC 
is proportional to neurodisability.61 It may be that the systemic inflammatory response 
associated with NEC results directly in brain injury,61 however, the causality is 
unproven and NEC could be a surrogate marker of other predisposing factors such as 
abdominal surgery, sepsis, organ immaturity or susceptibility to infection.61 detailed 
discussion of strategies to reduce NEC rates, which may provide neuroprotective 
benefit110, is beyond the scope of this review, but use of probiotics111, lactoferrin112, 
promotion of breast milk,113 114 avoidance of bovine-origin products114 and preventing 
infection are all likely to be beneficial.115 
 
Emerging Strategies 
Melatonin,116 erythropoietin117 and stem cell therapies118 have all shown 
neuroprotective potential in early studies and research is ongoing into these, and other 
interventions. First week protein and energy intake are associated with 18month 
developmental outcomes,119 and meta-analysis has shown that increasing early enteral 
nutrition may reduce neurodevelopmental impairment.120 Preterm infants fed with 
predominantly breast milk had higher deep nuclear grey matter volume at term 
corrected age,121 improved developmental scores at 18 months122 as well as higher IQ 
and academic achievement at 7 years,121 although this has not been seen in all 
studies.123 Research is ongoing into optimal nutritional regimens, however it is 
hypothesised the benefits of early nutrition and breast milk, including fortification, 
outweigh the risks.124 
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Interventions to ameliorate neurological sequelae following an initial brain injury are 
also being researched. An RCT comparing drainage, irrigation and fibrinolytic 
therapy with conventional management after severe IVH with posthaemorrhagic 
ventricular dilatation, reported a reduction in the incidence of death, severe cognitive 
and physical disability at two years in the intervention group.125 School age follow-up 
results will be published shortly. Developmental intervention in infants at risk of 
disability may also improve outcomes, however, due to the heterogeneity of trials, 
more research is required to determining what type of intervention is most 
beneficial.126  
 
 
SUMMARY AND CONCLUSIONS 
We present a review of interventions that are known to reduce the incidence of 
preterm brain injury and/or improve neurodevelopmental outcome. Although 
recommended, translation of this- like much other- research into practice is far from 
complete. Whilst research is ongoing in to new therapies and the relative importance 
and interplay of current strategies, broader awareness of available measures and their 
effective application may lead to improvement in neurodevelopmental outcome for 
the current cohort of premature infants. 
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